LanteRNA was founded by two research groups at Chalmers University of Technology through a research consortium called FormulaEx, and is now being developed further with partners such as Chalmers Ventures, ALMI Invest, Life Science Invest, and Marinvest. Today, the LanteRNA team operates near the teams at Chalmers University of Technology, maintaining a strong partnership to advance their research.
The innovation
mRNA are messenger molecules that normally are transcribed from our DNA to act as a “blueprint” for protein production in our cells. The Covid vaccines showcased a new way of utilizing mRNA, by directly delivering an external “blueprint” in the form of mRNA to instruct our bodies produce a treatment.
The technology developed by LanteRNA allows researchers to understand the delivery of mRNA and its effect in cells in greater depth, taking research and development of new mRNA pharmaceuticals to the next level.
“What we essentially did was to develop a more streamlined tracker inside of the mRNA, enabling analysis of mRNA uptake and interactions with higher precision”, says LanteRNA CEO Felix Mossberg.
By providing fluorescent nucleobase analogues, the LanteRNA technology opens new possibilities in analysing nucleotide-based therapeutics, often labelled as the medicines of the future. It is all but certain that mRNA-based therapies will make up a large percentage of the global pharmaceutics market ten years from now.
“Whether it ends up being 10, 20, or 30 percent of the global market, the rapid emergence of novel mRNA-based therapies benefits us as a commercial supplier of fluorescence-based products for this development.What we are most interested in is the potential of our innovation to change how mRNA research is undertaken, and we are eager to work with collaborators to push the field forward”, Felix Mossberg clarifies.
The future is already here
Traditional therapies often rely on introducing biomolecules to patients, tomorrow’s treatments will instead tap into patient’s own genetic machinery, revolutionizing how we treat diseases. This opens many possibilities to create personalized treatments, tailored to each patient’s unique biology. LanteRNA’s methods could play a role in enabling this transition.
“There are so many developers in our community and our line of work trying to crack the code of mRNA and its almost endless possibilities. We hope that we can do our part to enable these great developers with research tools in the future.“, says Felix Mossberg.
The personalised therapies of the future are no longer an inaccessible goal. They are already here. LanteRNA is working hard on speeding up the process by assisting researchers in their development of mRNA therapies.
